How to Help Your Patients Save Money on Rinvoq XR: A Provider's Guide to Savings Programs

Prescribing Rinvoq XR (upadacitinib) is only half the battle. With a wholesale acquisition cost of $7,090.41 per 30-day supply as of January 2026, cost is one of the top reasons patients abandon specialty medications within the first year. As the prescriber, having a working knowledge of every available savings program — and a workflow to enroll patients before they leave your office — is essential to keeping patients on therapy and achieving the clinical outcomes your prescribing decision intended.

Why Specialty Drug Costs Drive Non-Adherence

Research consistently shows that high out-of-pocket costs for specialty drugs are a leading predictor of non-adherence. For Rinvoq XR patients, cost barriers typically arise from three scenarios:

High copay or coinsurance on specialty tier: Even with commercial insurance, specialty tier cost-share can be $500–$1,500+ per month without a savings card.

Insurance denial: PA denied or step therapy requirements not met, leaving patient uninsured for the drug.

No insurance: Uninsured patient with $7,000+ monthly cash price.

Each scenario has a corresponding solution. Here's your complete reference.

Program 1: Rinvoq Complete Savings Card (Commercial Insurance)

For commercially insured patients, the Rinvoq Complete Savings Card is the most impactful cost-reduction tool available:

Cost as low as $5/month (savings depend on drug copay; actual copay may be $0 if copay is low enough)

Maximum $14,000 savings per calendar year

Enrollment at rinvoq.com or 1-800-274-6867

Card delivered by email; can be used at specialty pharmacy at point of dispensing

Eligibility restrictions: Not available to patients enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded insurance program. Using this card for government-insured patients constitutes illegal inducement under federal law.

Clinical practice tip: Have your office staff enroll the patient in the savings card at the time of prescribing, before they leave the office. Proactive enrollment dramatically reduces the chance of the patient abandoning the prescription due to sticker shock at the pharmacy.

Program 2: myAbbVieAssist — Patient Assistance for Uninsured/Underinsured Patients

For patients without insurance coverage or who have been denied coverage:

Free Rinvoq XR for up to 12 months for approved patients

Renewable — patients can reapply as needed

Eligibility based on income and insurance status

Apply via myAbbVieAssist.com or by calling AbbVie at 1-800-274-6867

Coverage-denied bridge: In some cases, AbbVie can provide free medication to commercially insured patients while their PA appeal is pending. Ask the Rinvoq Complete Hub (1-800-274-6867) about this option.

Program 3: Medicare Part D in 2026 — Key Changes That Help Patients

Medicare Part D in 2026 includes the Inflation Reduction Act's $2,100 annual out-of-pocket cap — a significant change that substantially reduces total annual patient cost for specialty drugs like Rinvoq XR. Key details for providers:

Once a Medicare Part D patient reaches the $2,100 OOP cap, their plan covers 100% for the remainder of the year

The Medicare Prescription Payment Plan (MPPP) lets patients spread annual OOP costs into equal monthly installments — particularly helpful for patients who can't handle high upfront costs

Extra Help (Low-Income Subsidy) — eligible patients may pay as little as $12.15 per prescription. Refer patients who may qualify to SSA.gov to apply.

AbbVie's Insurance Specialists (1-800-274-6867) can help your Medicare patients understand their specific cost under their plan

Program 4: Independent Non-Profit Patient Assistance Organizations

For Medicare patients (who cannot use the manufacturer savings card) or patients with partial insurance coverage, non-profit organizations can bridge the gap:

Patient Advocate Foundation Co-Pay Relief (CoPAR) — disease-specific copay assistance including for Medicare patients. Visit patientadvocate.org/copay-relief.

HealthWell Foundation — provides disease-specific grants; check for active programs at healthwellfoundation.org.

PAN Foundation — provides grants for underinsured patients on a disease-specific basis; panfoundation.org.

National Organization for Rare Disorders (NORD) — for conditions classified as rare, including GCA; rarediseases.org.

Building a Rinvoq XR Cost-Support Workflow in Your Practice

Systematizing cost support reduces patient abandonment and calls back to your office. Recommended practice workflow:

At the prescribing visit: Identify insurance type (commercial, Medicare, Medicaid, uninsured). Flag the appropriate savings pathway.

For commercial patients: Enroll in Rinvoq Complete Savings Card before they leave. Route prescription to in-network specialty pharmacy.

For uninsured or underinsured patients: Initiate myAbbVieAssist application immediately. Contact AbbVie's Hub for bridge supply if needed.

For Medicare patients: Review Part D plan details. Assess Extra Help eligibility. Refer to PAF, HealthWell, or PAN if coverage gap remains.

If PA is denied: Submit appeal with complete documentation. Contact AbbVie Hub for bridge support. Consider peer-to-peer review.

Medfinder for Providers: Real-Time Inventory Support

Once a patient's cost access is resolved, the final barrier is pharmacy availability. Medfinder for Providers offers real-time specialty pharmacy inventory data so you can help patients find their specific Rinvoq XR dose in stock — eliminating the unnecessary back-and-forth between patient, pharmacy, and your office.

Quick Reference: Rinvoq XR Savings by Patient Type

Commercial insurance: Rinvoq Complete Savings Card → as low as $5/month (up to $14,000/year savings)

Uninsured or underinsured: myAbbVieAssist → free medication up to 12 months, renewable

Medicare Part D: $2,100 OOP cap in 2026; Extra Help for low-income patients; PAF/HealthWell/PAN for gaps

PA denied: Bridge supply from AbbVie; appeals process; myAbbVieAssist if commercially insured and denied